Answers are grounded in this paper and cite their sources.
Finds GBP5 aggravates acute lung injury through NLRP3 inflammasome activation, indicating a potential pathway for therapy.
Guanylate-binding protein 5 (GBP5) is an interferon-inducible GTPase that promotes NLRP3 inflammasome activation. However, its role in acute lung injury (ALI) and its relationship with compensatory anti-inflammatory pathways remain poorly defined. Methods: We employed an LPS-induced ALI mouse model with AAV-mediated intratracheal GBP5 knockdown, transcriptomic profiling (RNA-seq), and in vitro studies in THP-1 macrophages. GBP5 overexpression and CD73 overexpression were used to dissect the GBP5-HIF-1α-CD73-adenosine axis. RNA-seq analysis of LPS-induced lung injury revealed upregulation of GBP family members (particularly GBP5) and multiple adenosine metabolism genes. AAV-mediated GBP5 knockdown in male C57BL/6 mice (6-8 weeks, n = 10/group) attenuated LPS-induced lung injury, reduced NLRP3 inflammasome activation (NLRP3, ASC, cleaved caspase-1), and decreased inflammatory cytokine levels (IL-1β, IL-6, TNF-α). In parallel, GBP5 knockdown suppressed CD73 and ADORA2A expression, whereas GBP5 overexpression in THP-1 macrophages enhanced CD73 expression via HIF-1α-dependent transcriptional activation confirmed by dual-luciferase reporter assays. CD73 overexpression in turn elevated cAMP/p-CREB signaling and suppressed NLRP3 inflammasome activity. GBP5 exacerbates ALI through NLRP3 inflammasome activation while simultaneously driving a compensatory HIF-1α-CD73-adenosine-cAMP-CREB feedback loop that restrains excessive inflammation. Targeting this dual pathway may offer novel therapeutic strategies for ALI and ARDS.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: